BMS' cancer drug is nearly 4 times the median American income, making the drug unaffordable
Register to read the full analysis —or— Upgrade to access more features
#cost
#price
#pricing
#returns
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue